Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Jingjing Jiang et al.|Nature|2024Cited by 175
Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Andrew M. Waters et al.|Cancer Research|2022Cited by 160
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E. Klomp, Clint A. Stalnecker|Science|2024Cited by 79
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.Mareen Lüthen, Sehrish Javaid, Jennifer E. Klomp et al.|UNC Libraries|2024Cited by 12
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N. Wasko, Miroslav Sekulic, Yingyun Wang et al.|Nature|2024Cited by 5